Die Rolle der Prostaglandine in der Entstehung von Gefäßveränderungen bei Diabetikern

 

^* Ich danke Claudia Dadak und Sonja Reiter für ihre Mitarbeit bei der Erstellung des Manuskriptes.

• LITERATUR

• 1 Auerswald W, Sinzinger H. Altersabhängiges Verhalten der Plättchensensitivität für antiaggregatorische Prostaglandine. Wr. Tierärztl. Mschr 1981; 68: 332-335.
• 2 Axelrod L, Levine L. Plasma prostaglandin levels in rats with diabetes mellitus and diabetic ketoacidosis. Diabetes 1982; 31: 994-1001.
• 3 Betteridge D. J, El Tahir K. E. H, Reckless J. P. D, Williams K. I. Platelets from diabetic subjects show diminished sensitivity to prostacyclin. Europ. J. Clin. Invest 1982; 12: 395-398.
• 4 Coughlin S, Meshkowitz M. A, Zetter B. R, Antoniades H. N, Levine L. Platelet dependent stimulation of prostacyclin synthesis by platelet derived growth factor. Nature 1981; 288: 600-603.
• 5 Davis T. M. E, Mitchell M. D, Dornan T. L, Turner R. C. Plasma 6-keto-PGF₁alpha concentrations and diabetic retinopathy. Lancet 1980; I: 373
• 6 Davis T. M. E, Mitchell M. D, Turner R. C. Prostacyclin and thromboxane metabolites in diabetes. Lancet 1980; I: 789-790.
• 7 Dollery C. T, Friedman L. A, Hensby C. N, Kohner E, Lewis P. J, Porta M, Webster J. Circulating prostacyclin may be reduced in diabetes. Lancet 1979; II: 1365
• 8 Garcia-Conde H, Amado J. A, Merino J, Bluet J. Prostaglandins and platelet function in diabetes. Thromb. Haemost 1979; 42: 789
• 9 Gryglewski R. J, Szczeklik A. Prostacyclin and atherosclerosis. In Lewis P. J, O’Grady J. Clinical Pharmacology of Prostacyclin Raven Press; New York: 1981: 89-95.
• 10 Halushka P. V, Rogers P. C, Loadholt C. B, Colwell J. A. Increased platelet thromboxane A₂ biosynthesis in diabetes mellitus. J. Lab. Clin. Med 1981; 97: 87-96.
• 11 Hamberg M, Svensson J, Samuelson B. Thromboxane: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Nat. Acad. Sci. USA 1975; 72: 2294-2298.
• 12 Harrison H. E, Reece A. H, Johnson M. Decreased vascular prostacyclin in experimental diabetes. Life Sciences 1978; 23: 351-356.
• 13 Harrison H. E, Reece A. J, Johnson M. Effect of insulin treatment on prostacyclin in experimental diabetes. Diabetologia 1980; 18: 65-68.
• 14 Hope W, Chesterman G. J, Dusting G. J, Smith F. J, Morgan I, Martin T. J. Inhibition by ß-thromboglobulin of prostacyclin (PGI₂) formation in arterial endothelial cells. Thromb. Haemost 1979; 42: 8
• 15 Johnson M, Harrison H. E, Raftery A. T, Elder J. B. Vascular prostacyclin may be reduced in diabetes in man. Lancet 1979; I: 325-326.
• 16 Johnson M, Reece A. H, Harrison H. E. Decreased vascular prostacyclin in experimental diabetes. Adv. Pharmacol. Chemother 1979; a 4: 856-869.
• 17 Johnson M, Reece A. M, Harrison H. E. An imbalance in arachidonic acid metabolism in diabetes. Adv. Prostagl. Thromb. Res 1980; 8: 1283-1286.
• 18 Johnson M, Reece A. H, Harrison H. E. An imbalance in arachidonic acid metabolism in human and experimental diabetes. Artery 1980; a 6: 81-86.
• 19 Johnson M, Harrison H. E, Raftery A. T, Elder J. B. Prostacyclin and diabetes. In Lewis P. J, O’Grady J. Clinical Pharmacology of prostacyclin Raven Press; New York: 1981: 105-112.
• 20 Karpen C. W, Pritchard K. A, Arnold J. H, Cornwell D. G, Panganamala R. V. Restoration of prostacyclin/thromboxane A₂ balance in the diabetic rat: influence of dietary vitamin E. Diabetes 1982; 31: 947-951.
• 21 Klein K, Kaliman J, Sinzinger H, Silberbauer K. Plättchensensitivität für Prostacyclin bei diabetischen und nicht-diabetischen Patienten mit atherosklerotischen Gefäßveränderungen – ein Maß für die Prostaglandinrezeptoren. VASA 1980; 9: 123-129.
• 22 Leithner Ch, Winter M, Silberbauer K, Wagner O, Pinggera W. F, Sinzinger H. Enhanced prostacyclin availability from blood vessels in uremic humans and rats. Proc. EDTA 1978; 12: 418-422.
• 23 MacIntyre D. E, Pearson J. D, Gordon J. L. Localization and stimulation of prostacyclin production in vascular cells. Nature 1978; 271: 549-551.
• 24 Marks H. H, Krall L. P. Onset, course, prognosis and mortality in diabetes mellitus. In Marble A, White P, Pradley R. F, Krall L. P. Joslin’s Diabetes mellitus Lea & Febiger; 1971: 186 ff
• 25 Moncada S, Gryglewski R. J, Bunting S, Vane J. R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663-665.
• 26 Moncada S, Higgs E. A, Vane J. R. Human arterial and venous rings generate prostacyclin a potent inhibitor of platelet aggregation. Lancet 1977; I: 18-21.
• 27 Ondodeva H, Hirata T, Sugawara H, Sugai K, Yoda B, Toyota T, Goto Y. Platelet sensitivity to adenosine diphosphate and to prostacyclin in diabetic patients. Tohoku J. exp. Med 1982; 137: 423-428.
• 28 Ross R, Glomset J. A. The pathogenesis of atherosclerosis. The New Engl. J. Med 1976; 295: 369-377.
• 29 Schernthaner G, Silberbauer K, Sinzinger H, Müller M. Plasma ß-thromboglobulin and glycosylated hemoglobin in type I and type II diabetes mellitus. Thromb. Haemost 1979; 42: 334
• 30 Schernthaner G, Sinzinger H, Silberbauer K, Freyler H. Altered platelet funtion in diabetes mellitus. Decrease of vascular prostacyclin, analysis of plasma ß-thromboglobulin and platelet factor 4 according to state of metabolic control and diabetic microangiopathy stages. In Tesi M. 1st Int. Coll. Angiology Academic Press; New York – London: 1980: 277ff
• 31 Schrör K, Rösen P. Increased prostacyclin release from perfused hearts of acutely diabetic rats. Diabetologia 1980; 61: 391-394.
• 32 Siegl A. M, Smith J. B, Silver M. J, Nicolaou K. C, Ahern D. Selective binding site for ³H-prostacyclin on platelets. J. Clin. Invest 1979; 63: 215-223.
• 33 Silberbauer K, Schernthaner G, Sinzinger H, Piza-Katzer H, Winter M. Decreased vascular prostacyclin in juvenile-onset diabetes. The New Engl. J. Med 1979; 300: 366-367.
• 34 Silberbauer K, Sinzinger H, Winter M. Prostacyclin activity in rat kidney stimulated by angiotensin II. Brit. J. exp. Pathol 1979; 60: 38-44.
• 35 Silberbauer K, Schernthaner G, Sinzinger H, Clopath P, Piza-Katzer H, Winter M. Diminished prostacyclin generation in human and experimentally induced (streptozotocin, alloxan) diabetes mellitus. Thromb. Haemost 1979; 42: 334
• 36 Sinzinger H, Silberbauer K, Winter M. Prostacyclin formation by vascular smooth muscle cells. Lancet 1978; I: 1352-1353.
• 37 Sinzinger H, Silberbauer K, Auerswald W. Prostacyclin formation by human vascular wall. Atherosclerosis 1979; V: 140-143.
• 38 Sinzinger H, Silberbauer K, Oppolzer R, Winter M, Auerswald W. Prostacyclin (PGI₂)-generation by different types of human atherosclerotic lesions. Exp. Pathol 1980; 18: 175-178.
• 39 Sinzinger H, Silberbauer K, Clopath P, Schernthaner G. Effect of experimentally induced diabetes on swine vascular prostacyclin (PGI₂) synthesis. Artery 1981; 8: 30-36.
• 40 Sinzinger H, Auerswald W. Temporary increase in vascular prostacyclin in experimental diabetes. Proc. Acad. Sci 1981; 26: 24-35.
• 41 Sinzinger H, Schernthaner G, Kaliman J. Sensitivity of platelets to prostaglandins in coronary heart disease and angina pectoris. Prostaglandins 1982; 22: 773-781.
• 42 Sinzinger H, Kaliman J, Kefalides A, Christa Hoche, Peskar B. A. The prostacyclin synthesis stimulating plasma factor is unchanged in acute angina pectoris. im Druck 1983
• 43 Sinzinger H. W. Firbas: Gefäßwandzellen synthetisieren Thromboxan. Wr. Klin. Wschr. (in press). 1983
• 44 Webster J. M. Porta, Hensby C. N, Kohner E. M, MacDermot J, Lewis P. J. Plasma levels of 6-oxo-PGF₁alpha, the hydrolysis product of prostacyclin may be reduced in diabetes. In Lewis P. J, O’Grady J. Clinical Pharmacology of prostacyclin 113-116. Raven Press; New York: 1981
• 45 Ziboh V. A, Maruta H, Lord J, Cagel W. D, Lucky W. Increased biosynthesis of thromboxane A₂ by diabetic platelets. Europ. J. Clin. Invest 1979; 9: 223-228.